Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tempest Therapeutics Inc (NQ: TPST )

1.795 +0.045 (+2.57%)
Streaming Delayed Price Updated: 3:10 PM EDT, Jul 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Tempest Therapeutics Inc

< Previous 1 2 Next >
Tempest to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From Tempest Therapeutics
Via GlobeNewswire
Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update
From Tempest Therapeutics
Via GlobeNewswire
Tempest Announces Publication in Cancer Research Communications Highlighting TPST-1495 Significantly Increased Potency Against Prostaglandin-Driven Tumor Models by Blocking EP2 and EP4 Together
From Tempest Therapeutics
Via GlobeNewswire
Tempest to Present at the Jefferies Global Healthcare Conference
From Tempest Therapeutics
Via GlobeNewswire
Tempest to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers
From Tempest Therapeutics
Via GlobeNewswire
Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Tempest Therapeutics
Via GlobeNewswire
Tempest Reports First Quarter 2023 Financial Results and Provides Business Update
From Tempest Therapeutics
Via GlobeNewswire
Tempest Therapeutics (NASDAQ: TPST) Reports Strong Early Results From Phase 1b/2 Study of TPST-1120 in Hepatocellular Carcinoma
Tempest Therapeutics, Inc. (NASDAQ: TPST) is engaged as a clinical-stage oncology company, which is focused on the research and development 
Via Spotlight Growth
Tempest Announces Positive Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma
From Tempest Therapeutics
Via GlobeNewswire
Tempest to Report Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma
Webcast Conference Call Friday, April 28, 2023, at 8:30 a.m. ET 
From Tempest Therapeutics
Via GlobeNewswire
Tempest Announces TPST-1495 Poster Presentation at the 2023 ASCO Annual Meeting
From Tempest Therapeutics
Via GlobeNewswire
Tempest Announces New Translational and Preclinical Data Presented at the 2023 AACR Annual Meeting
From Tempest Therapeutics
Via GlobeNewswire
Tempest Reports Year End 2022 Financial Results and Provides Business Update
From Tempest Therapeutics
Via GlobeNewswire
Tempest to Present Biomarker Data for TPST-1120 at the Society for Immunotherapy of Cancer (SITC) 2023 Spring Scientific Meeting
From Tempest Therapeutics
Via GlobeNewswire
Tempest to Present New Translational and Preclinical Data at the 2023 AACR Annual Meeting
From Tempest Therapeutics
Via GlobeNewswire
Tempest to Present at the Piper Sandler 34th Annual Healthcare Conference
From Tempest Therapeutics
Via GlobeNewswire
Tempest Presents Data Showing TPST-1120-Induced Pharmacodynamic Changes Consistent with Clinical Benefit Observed in Patients with Cancer
From Tempest Therapeutics
Via GlobeNewswire
Tempest Reports Third Quarter 2022 Financial Results and Provides Business Update
From Tempest Therapeutics
Via GlobeNewswire
Tempest Announces Data Presentations, including a Late-Breaking Presentation on TPST-1120, at the SITC Annual Meeting
TPST-1495 also will be featured in a separate presentation 
From Tempest Therapeutics
Via GlobeNewswire
Tempest to Present at Emerging Technologies for IO Targeting and Discovery Summit
From Tempest Therapeutics
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.